Breast cancer drug shown to reduce recurrence risk

A drug developed by Swiss pharmaceutical maker Novartis has now been shown to reduce this risk by a quarter in a large group of early-stage survivors, offering patients new hope.

"The current standard of therapy for these patients is surgery followed by chemotherapy... or radiation, then followed by between five and 10 years of hormonal blockade by various endocrine therapies," lead author Dennis Slamon of the UCLA Jonsson Comprehensive Cancer Center told reporters. Half the patients received ribociclib—marketed under the brand name Kisqali—as well as hormonal therapy, while the other half received only hormonal therapy. They continued for a treatment period of three years.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Study suggests licorice-derived liquiritigenin has breast cancer prevention potential for high-risk postmenopausal womenResearchers evaluated the potential of three licorice (Glycyrrhiza) species, i.e., G. glabra (GG), G. uralensis (GU), and G. infata (GI), and hops (Humulus lupulus), and their main bioactive polyphenols, to prevent breast malignancy.
Source: NewsMedical - 🏆 19. / 71 Read more »

'We had the little-known type of breast cancer that rarely causes lumps or shows on mammograms'Emma Amos and seven other women who were diagnosed with lobular breast cancer formed a charity after finding there was little support and information 🖋️ claudiatanner claudiatanner
Source: i newspaper - 🏆 8. / 89 Read more »